Business

As more blockbuster drugs come off patent, generic drugmakers face a changing landscape. Meredith Wadman looks at their strategies for survival.

Although cargo vessels are currently spared emissions restrictions, the industry is planning ahead. Kurt Kleiner looks at the ideas being floated to improve energy efficiency on the high seas.

The flat-screen television boom has materials scientists scrambling to replace the valuable metal oxide that coats the screens. Andrea Chipman reports.

Sustained high oil prices won't be enough to make coal liquefaction economically viable without large-scale public investment. Katharine Sanderson reports.

Life for scientific entrepreneurs in Russia can be fraught with difficulty. Alison Abbott meets one who has ridden the rapids for more than a decade.

Europe's largest technology company is switching its priorities, even as it faces a growing bribery scandal. Quirin Schiermeier reports.

Can an expanded loan guarantee programme dispel US power companies' hesitation about resuming construction of nuclear power plants? Geoff Brumfiel investigates.

Plans to revamp drug regulation in China have yet to convince the sceptics, as Jane Qiu reports.

Smart investors who know the drugs business well are helping to make Zurich's stock market a popular place for biotechnology firms to raise money. Andrea Chipman reports.

The safety problems that brought down Vioxx have tainted a whole class of drugs. Meredith Wadman examines their chances of a comeback.

The US Patent and Trade Office has cracked open the door on its normally closed patent evaluation process. Heidi Ledford looks at how its peer-review project is faring.